Drug Trial Radar · NCT07652073
A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 15, 2026
Primary completion
Nov 30, 2027
Study completion Mar 30, 2028
Sponsor
- Lead sponsor
- Danatlas Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, multicenter, single-arm dose expansion trial planned to enroll up to 30 subjects with advanced or metastatic ovarian cancer. The Objective is to conduct a preliminary evaluation of the efficacy, the safety, tolerability and PK profile of DAT-2645
Conditions
- Advanced or Metastatic Ovarian Cancer
Interventions
DAT-2645 tabletDrug
Oral administration with 21 days each cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate ( ORR )Time frame: Approximately 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Research site
Beijing, China
Research site
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.